spacer
home > ebr > winter 2003 > capturing recombinant proteins
PUBLICATIONS
European Biopharmaceutical Review

Capturing Recombinant Proteins

Recombinant DNA technologies are widely used in the drug discovery process, not only to produce novel, engineered proteins, but also to generate proteins in the quantities required for downstream research. Purifying these proteins remains a bottleneck. This article looks at a novel method to rapidly isolate structurally and functionally intact histidine-tagged recombinant proteins using superparamagnetic beads.

Recombinant DNA (rDNA) technologies are a cornerstone of the biotechnology industry and have revolutionised approaches to the discovery of new medicines. Pioneered by scientists such as Paul Berg, Stanley Cohen and Herbert Boyer in the early 1970s, rDNA methodologies allow scientists to 'cut and paste' DNA to engineer novel proteins, and to transfer DNA from one organism to another. They also provide the means to generate proteins in the quantities required for downstream studies in drug discovery - from target identification, target validation and screening of compound libraries, to ADME-Tox studies.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Beate Rygg Johnsen, Product Manager at Dynal Biotech

Beate Rygg Johnsen is an International Product Manager at Dynal Biotech, Oslo in Norway and is responsible for the company's efforts within the area of proteomics. Beate is driving Dynal Biotech's penetration in drug discovery. She holds a MSc and a Cand Scienct from the University of Oslo, Institute of Biochemistry, and a degree in marketing management from BI, Norwegian School of Management.

spacer
Beate Rygg Johnsen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health and ActiGraph simplify clinical trial activity and sleep monitoring for patients, sites, and sponsors with their new integration

Philadelphia, PA – November 14, 2019: Signant Health, formerly CRF Health and Bracket, is proud to announce that it has integrated its industry leading eCOA platform TrialMax®, with ActiGraph’s CentrePoint system. The integration, which includes ActiGraph’s FDA 510(k) cleared sensors, helps simplify the process of collecting and monitoring real-world activity, mobility, and sleep outcomes data for patients and researchers.
More info >>

White Papers

Using Device Strategy to Drive R&D Productivity

Phillips-Medisize


More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement